Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Neoadjuvant and adjuvant breast cancer studies available for your patients

Consider referring your newly diagnosed breast cancer patients to a clinical trial evaluating investigational drug(s) in combination with standard of care.

Although less than 1% of all breast cancers are diagnosed in men worldwide,(2) men may also be eligible for a breast cancer clinical trial.

Although less than 1% of all breast cancers are diagnosed in men worldwide,(2) men may also be eligible for a breast cancer clinical trial.

Breast cancer clinical trials are currently researching the use of investigational drugs for those with unmet needs

  • Cancer cells develop mechanisms to evade immune detection, which can result in tumor progression.
  • Checkpoint inhibition targets regulatory pathways of the immune system and in this study we are investigating whether it has the potential to reduce self-tolerance and enhance anti-tumor immune responses.
  • Data from clinical studies3-6 may support the addition of immuno-oncology drugs to improve outcomes in patients with breast cancer.
Bristol Myers Squibb promotes health equity and seeks to improve the health outcomes of populations disproportionately affected by serious diseases. We are committed to reaching these underserved communities—regardless of race, nationality, or heritage—through our clinical trial programs.

Consider the subtype first, then discuss active clinical trials with your patients

Identify patients based on histological and molecular profiles

Review the importance of primary breast cancer subtypes when discussing trial eligibility with your patients (including men):

ER+/HER2- BREAST CANCER (estrogen receptor positive - sometimes referred to as HR+ or Hormone Receptor positive / human epidermal growth factor receptor 2-positive)

This is a subtype of breast cancer that cancer cells test positive for a receptor proteins that bind to estrogen (ER) and test negative for a protein called human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is sensitive to treatment with anti-estrogen hormone (endocrine) therapies.

HER2+ BREAST CANCER (human epidermal growth factor receptor 2-positive)

This is a subtype of breast cancer that cancer cells test positive for HER2. This protein promotes the growth of cancer cells. HER2-positive breast cancers tend to be aggressive and are sensitive to HER2-directed therapies.

TRIPLE-NEGATIVE BREAST CANCER (ER-, PR-, HER2-)

This is a subtype of breast cancer that cancer cells test negative for ER, a receptor protein that binds to progesterone (PR) and HER2. This subtype of breast cancer tends to grow and spread faster than other types of breast cancers and are not sensitive to endocrine therapies and HER2-directed therapies.

ER+/HER2- Breast Cancer is associated with good prognosis when diagnosed early and treated appropriately, however recurrences and an increased risk of death persist over time.(7)

Your insights help patients understand their options

An open dialogue with your patients may give them a better understanding of clinical trials. By starting a conversation based on your expert guidance, patients gain the knowledge to confidently make choices regarding the next step in their care. 

Based on survey results from 200 practitioners, 87% of oncologists believe clinical trials provide high-quality care.8

How to refer your patients

Find a trial and a recruiting physician to refer your patient

When referring a patient to a study, please be assured that you will continue to provide primary care for the patient. Study staff will provide study-related care only. 

Connect eligible patients with appropriate trials

If you have a patient you think may qualify for a clinical trial, you can discuss patient eligibility by referring them to a principal investigator.

4 steps to successful patient enrollment

Now enrolling: BMS clinical trials in ER+/HER2- primary breast cancer

Click the links below to review complete eligibility criteria, study site locations, and contact information for these studies.

Our vision is to discover, develop, and deliver transformational medicines for patients through our internal discovery efforts and innovative collaborations.



References:

1. AACR Publications/Cancer Research/Abstract 4191: The Worldwide female breast cancer incidence and survival, 2018; Zoubida Zaidi and Hussain Adlane Dib; DOI: 10.1158/1538-7445. AM2019-4191. Published July 2019. 2. ABC Global Alliance. Breast cancer worldwide. Available at: https://www.abcglobalalliance.org/articles/breast-cancer-worldwide/. Accessed February 24, 2020. 3. Schmid P, Park YH, Muñoz-Couselo E, et al. Pembrolizumab (Pembro) + chemotherapy (Chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(suppl_15):556-6. 4. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. The New England Journal of Medicine. 2018;379;2108-21. 5. Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY2. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(suppl_15):506. 6. Loibl S, Untch M, Burchardi N, et al. Randomized Phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2018;36(15_suppl):104. 7. Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer: Basic and Clinical Research. 2016;10:103-6. 8. Somkin CP, Altschuler A, Ackerson L, et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care. 2005;11:413-421.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com